Risitano, A., Weitz, I. C., De Castro, C. M., Kiladjian, J.-J., Griffin, M., Nishimori, H., … de Latour, R. P. (2021). Categorized hematologic response to pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria: post hoc analysis of data from a phase 3 randomized trial (PEGASUS). In BRITISH JOURNAL OF HAEMATOLOGY (Vol. 193, pp. 24–25).

Risitano, Antonio, Ilene C. Weitz, Carlos M. De Castro, Jean-Jacques Kiladjian, Morag Griffin, Hisakazu Nishimori, Mohamed Hamdani, Temitayo Ajayi, Scott B. Baver, and Regis Peffault de Latour. “Categorized hematologic response to pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria: post hoc analysis of data from a phase 3 randomized trial (PEGASUS).” In BRITISH JOURNAL OF HAEMATOLOGY, 193:24–25, 2021.

Risitano A, Weitz IC, De Castro CM, Kiladjian J-J, Griffin M, Nishimori H, et al. Categorized hematologic response to pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria: post hoc analysis of data from a phase 3 randomized trial (PEGASUS). In: BRITISH JOURNAL OF HAEMATOLOGY. 2021. p. 24–5.

Risitano, Antonio, et al. “Categorized hematologic response to pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria: post hoc analysis of data from a phase 3 randomized trial (PEGASUS).” BRITISH JOURNAL OF HAEMATOLOGY, vol. 193, 2021, pp. 24–25.

Risitano A, Weitz IC, De Castro CM, Kiladjian J-J, Griffin M, Nishimori H, Hamdani M, Ajayi T, Baver SB, de Latour RP. Categorized hematologic response to pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria: post hoc analysis of data from a phase 3 randomized trial (PEGASUS). BRITISH JOURNAL OF HAEMATOLOGY. 2021. p. 24–25.